

# Caladrius Biosciences Inc

08:40 20 Jun 2018

## Caladrius Biosciences shares pop after FDA bestows favourable designation on its chronic coronary artery disease treatment

Investors sent shares of Caladrius Biosciences Inc (NASDAQ:CLBS) flying Tuesday after the US Food and Drug Administration bestowed a regenerative medicine advanced therapy (RMAT) designation on its late-stage CD34+ cell therapy program for the treatment of chronic coronary artery disease.

By the closing bell, Caladrius Biosciences finished up a whopping 67% to US\$6.61. Investors continued to rally the shares in extended trading, adding another 60% to US\$10.60.

The FDA grants the RMAT designation to regenerative medicine therapies that intend to treat serious conditions and show considerable potential. RMAT includes all the benefits of the FDA's fast track and breakthrough designations, including early-stage discussions between the FDA and the pharma company involved.

"We are delighted and encouraged that the FDA has recognized our CD34+ cell therapy program with an RMAT designation," said David Mazzo, Caladrius's president and chief executive officer. "Refractory angina is a serious condition with high morbidity and no known effective treatments. We look forward to working with the FDA to define a path to registration for our therapy with the aim of providing expeditious treatment to patients suffering from this condition," he added.

Caladrius acquired an exclusive international license to the late-stage CD34+ program from the pharmaceutical group Shire Plc in March of this year. This acquisition included Phase 1, 2 and 3 clinical study data of CD34+ cell therapy as a treatment for no-option refractory angina, along with the related regulatory filings.


As many as 1 million people in the US have chronic symptomatic coronary artery disease, (also known as refractory angina), that is stubbornly difficult to treat with medical therapy. The symptoms of the disease include chest pain, shortness of breath and fatigue.

--Updates share price--

**Price:** 1.71

**Market Cap:** \$33.04 m

### 1 Year Share Price Graph



October 2019    April 2020    October 2020

### Share Information

**Code:** CLBS

**Listing:** NASDAQ

52 week	High	Low
	3.58	1.15

**Sector:** Pharma & Biotech

**Website:** [www.caladrius.com](http://www.caladrius.com)

### Company Synopsis:

*Caladrius is a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies for select cardiovascular and autoimmune diseases. Our leadership team collectively has decades of biopharmaceutical development experience and world-recognized scientific achievement in the fields of cardiovascular and autoimmune disease, among other areas.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.